Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Breathing01:05

Breathing

58.9K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
58.9K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

124
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

246
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
246

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravenous ketamine for emergency department treatment of suicidal ideation in a paediatric population: protocol for a double-blind, randomised, placebo-controlled, parallel-arm pilot trial (KSI study).

BMJ open·2024
Same author

Comparative Effectiveness of Pediatric Integrative Medicine: A Pragmatic Cluster-Controlled Trial.

Children (Basel, Switzerland)·2021
See all related articles

Related Experiment Video

Updated: Jun 14, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.4K

Considerations for the use and study of exogenous surfactant in respiratory disease from COVID-19.

Michael P Schlegelmilch1

  • 1Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
|June 12, 2025
PubMed
Summary
This summary is machine-generated.

Exogenous surfactant therapy, studied for acute respiratory distress syndrome (ARDS), shows potential in early COVID-19 respiratory disease. Further research is needed to explore benefits in specific patient groups.

Keywords:
ARDSCOVID-19surfactant

More Related Videos

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

4.7K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.7K

Related Experiment Videos

Last Updated: Jun 14, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.4K
A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

4.7K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.7K

Area of Science:

  • Pulmonary Medicine
  • Critical Care
  • Infectious Diseases

Background:

  • Exogenous surfactant therapy has been investigated for acute respiratory distress syndrome (ARDS) with limited success in mortality benefit.
  • The COVID-19 pandemic has prompted a re-evaluation of surfactant therapy for respiratory complications.

Purpose of the Study:

  • To explore the potential benefits of exogenous surfactant therapy in COVID-19 respiratory disease.
  • To investigate if patients early in their disease course, not meeting full ARDS criteria, may respond favorably to surfactant therapy.

Main Methods:

  • Review of existing clinical trials and biological plausibility.
  • Analysis of potential differential responses in specific patient populations.

Main Results:

  • Previous trials in severe ARDS have not demonstrated mortality benefits.
  • Biological rationale suggests potential benefits in earlier or less severe disease stages.

Conclusions:

  • Patients with COVID-19 respiratory disease, particularly those in early stages or not meeting full ARDS criteria, may represent a distinct population for surfactant therapy investigation.
  • Future clinical trials should consider stratifying patients to identify those who might benefit from exogenous surfactant.